Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 13, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Ebola Virus Infection
Interventions
DRUG

B/Current Standard of Care Plus ZMapp

Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus

OTHER

A/Current Standard of Care Alone

Optimized standard of care for Ebola virus infection

Trial Locations (11)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

CTE Forecariah, Forécariah

Monrovia Medical Unit, Monrovia

ELWA III Hospital, Paynesville

Police Training School 1 (PTS1), Western Rural District, Freetown

Emergency Ebola Treatment Unit, Goderich

Police Training School 2, Hastings

Chinese Friendship Hospital, Jui

International Medical Corps (IMC) Kambia, Kambia

International Medical Corps (IMC) Lunsar, Port Loko

Adventist Development and Relief Ebola Treatment Unit, Waterloo

All Listed Sponsors
collaborator

The Ministry of Health and Social Welfare, Liberia

UNKNOWN

collaborator

Ministry of Health and Sanitation, Sierra Leone

OTHER_GOV

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

The Ministry of Health and Public Hygiene, Guinea

UNKNOWN

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02363322 - Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection | Biotech Hunter | Biotech Hunter